-
so , although not invested financially, I am staying interested enough to watch a doco on the tele and read their presentation today.
So far they would seem to just spending the money on buildings and salaries and I guess developing skills though they also seem to be seeking others to provide them with flower. There are definitely some useful milestones passed though, such as GMP certification.
But as explained the road map to breakeven is end of calendar 2023. with first NZ sales of product early next year 2022, and first consignment as part of their secured contract is scheduled for delivery to Germany later next year. So still a while to pay salaries from investors pockets before revenue from significant sales.
I really couldnt invest in this company as it does seem a bit of a charitable vehicle for the locals and I'd be surprised if they can make hard decisions when necessary. But happy to keep in touch with their progress.
For clarity, nothing I say is advice....
-
Member
First time poster....
Agreed, I looked at this company and decided to invest some mildly speculative funds into Cannasouth. RUA seems to be quite complicated structurally, plus they don't seem to move as fast as comparable companies. Hopefully they do alright though.
My $0.02, cheers
-
Personally I hope they succeed and create something good near gisborne. Watching the first episodes of the doco they didn't seem very organised. I'll watch more on their progress but at this stage to me it's a crowded market globally and we might be too late to the party. On a plus medical canninis prices will get cheaper
-
Is this a negative spun into a positive??
https://www.nzx.com/announcements/408924
Rua Bioscience (NZX:RUA) announces the export-led company will cease local GMP manufacturing and accelerate its global brand strategy, building its international product pipeline while developing valuable points of difference in the areas of genetic discovery and novel product development. Working with manufacturing partners, Rua expects New Zealand patients will ultimately benefit from a wider range of affordable medicines.
CEO, Paul Naske, says Rua has been actively exploring where true value lies in the medicinal cannabis industry, where the company’s unique strengths can propel it, and how Rua can best serve the needs of patients and investors.
“To capture value and encourage growth we will focus on our key strengths – leveraging our global-scale supply agreement and established sales and marketing partnerships across Europe to build a sustainable global company, while our world-class cultivation team in Ruatorea works on unique genetics for our established and future product pipelines.”
Rua has focused on the high-growth European medicinal cannabis market, which is expected to be worth as much as NZ$3.9b by 2026 [1]. The company has significantly advanced plans for market entry in Germany, is positioning itself as an early mover in Poland, and investigating other emerging medicinal cannabis markets with the support of its European partners Nimbus and Motagon.
Chairman, Trevor Burt, says the Board believes this refinement is consistent with Rua’s founding strategy and reflects the benefit of Rua’s capital-efficient approach, which allows Rua to move with relative agility at global scale.
“As an export-led company, we have advanced negotiations in high-value European markets and are now assessing commercial opportunities in Australia, an exciting market right on our doorstep; our intellectual property strategy maintains its focus on plant discovery and breeding, and the formulation of unique finished products; and we remain committed to building a sustainable business that creates intergenerational opportunity in Te Tairawhiti,” he says.
Mr Naske says, the company will retain its focus on the supply of GMP-certified medicines and expects to do this in a more cost-effective and expedient way, particularly for New Zealand patients.
“Rua will work with manufacturing partners to build out our product portfolio while developing branded products utilising our internally developed IP.”
In the meantime, Rua is planning for continuity of supply for New Zealand patients.
“There is ample stocks of Rua medicine (with the appropriate shelf life) available through Rua’s distributor, with stock ring-fenced for patients on Rua’s compassionate access programme. The company remains committed to developing a domestic product pipeline, ensuring prescribers and patients have access to medicines, and will update prescribers with those details in the near future.”
The change impacts the manufacture of one product and results in the loss of two employees.
Rua recently released its Market Insights for 2023, which provides an overview of key markets Rua is focused on, both overseas and here in Aotearoa.
-
 Originally Posted by Sideshow Bob
Is this a negative spun into a positive??
https://www.nzx.com/announcements/408924
Rua Bioscience (NZX:RUA) announces the export-led company will cease local GMP manufacturing and accelerate its global brand strategy, building its international product pipeline while developing valuable points of difference in the areas of genetic discovery and novel product development. Working with manufacturing partners, Rua expects New Zealand patients will ultimately benefit from a wider range of affordable medicines.
CEO, Paul Naske, says Rua has been actively exploring where true value lies in the medicinal cannabis industry, where the company’s unique strengths can propel it, and how Rua can best serve the needs of patients and investors.
“To capture value and encourage growth we will focus on our key strengths – leveraging our global-scale supply agreement and established sales and marketing partnerships across Europe to build a sustainable global company, while our world-class cultivation team in Ruatorea works on unique genetics for our established and future product pipelines.”
Rua has focused on the high-growth European medicinal cannabis market, which is expected to be worth as much as NZ$3.9b by 2026 [1]. The company has significantly advanced plans for market entry in Germany, is positioning itself as an early mover in Poland, and investigating other emerging medicinal cannabis markets with the support of its European partners Nimbus and Motagon.
Chairman, Trevor Burt, says the Board believes this refinement is consistent with Rua’s founding strategy and reflects the benefit of Rua’s capital-efficient approach, which allows Rua to move with relative agility at global scale.
“As an export-led company, we have advanced negotiations in high-value European markets and are now assessing commercial opportunities in Australia, an exciting market right on our doorstep; our intellectual property strategy maintains its focus on plant discovery and breeding, and the formulation of unique finished products; and we remain committed to building a sustainable business that creates intergenerational opportunity in Te Tairawhiti,” he says.
Mr Naske says, the company will retain its focus on the supply of GMP-certified medicines and expects to do this in a more cost-effective and expedient way, particularly for New Zealand patients.
“Rua will work with manufacturing partners to build out our product portfolio while developing branded products utilising our internally developed IP.”
In the meantime, Rua is planning for continuity of supply for New Zealand patients.
“There is ample stocks of Rua medicine (with the appropriate shelf life) available through Rua’s distributor, with stock ring-fenced for patients on Rua’s compassionate access programme. The company remains committed to developing a domestic product pipeline, ensuring prescribers and patients have access to medicines, and will update prescribers with those details in the near future.”
The change impacts the manufacture of one product and results in the loss of two employees.
Rua recently released its Market Insights for 2023, which provides an overview of key markets Rua is focused on, both overseas and here in Aotearoa.
The announcement is complete jibberish really. The original thesis about growing quality cannabis in the East Coast, supporting the local economy and diversifying our horticultural economy, has been completely invalidated.
The company is a joke at this point and should probably de-list. I don't see that there is any value there.
-
Member
[QUOTE=Lego_Man;997180]The announcement is complete jibberish really. The original thesis about growing quality cannabis in the East Coast, supporting the local economy and diversifying our horticultural economy, has been completely invalidated.
The company is a joke at this point and should probably de-list. I don't see that there is any value there.[/QUOTE
To true Leggo man if the cannabis had been made legal as the greens wanted then this company would have prospered along with shareholders ,gawd help anyone who did not get out after that I P O
-
-
Good move
"First of its kind, a cultivation licence has been granted for research into an indigenous magic mushroom that is hoped to be able to help those suffering from methamphetamine addiction.
The Ministry of Health granted the licence for Psilocybe Weraroa, a variety of mushroom that contains psilocybin, the active ingredient in magic mushrooms.
Psilocybin is an illegal Class A substance under the Misuse of Drugs Act, but the Director-General of Health can grant licences for research or medicinal purposes.
The licence is held by Rua Bioscience, a biopharmaceutical company based in Tairāwhiti, and is a crucial piece of the puzzle in a collaboration with a long-term goal of helping whānau affected by methamphetamine and other addictions."
-
Member
You'd think they'd focus on their core business, getting product to market and increasing sales, once profitable play however they want, but until then the shareholders funds shouldn't be wasted.
-
Junior Member
I dont know if its really a waste of funds - mushrooms are probably not too difficult to grow - they already have the facilities for growing in controlled environments, so id imagine there wouldnt be too much more needed in terms of investment. I think this is a really good play, and it actually leverages using NZ native species, unlike the cannabis industry where the "local genetics" definitely arent NZ native - plus cannabis is a highly saturated industry with a race to the bottom for pricing. This is much more refreshing news copmpared to cannasouth revealing they need to cut 400k of spending in order to survive (despite keeping their top heavy exec and board structure since eqalis took them over)
Posting Permissions
- You may not post new threads
- You may not post replies
- You may not post attachments
- You may not edit your posts
-
Forum Rules
|
|
Reply With Quote
Bookmarks